AstraZeneca Requests US FDA Emergency Use Authorization for Covid-19 Prophylaxis
October 05 2021 - 2:43AM
Dow Jones News
By Jaime Llinares Taboada
AstraZeneca PLC said Tuesday that it has requested an Emergency
Use Authorization to the U.S. Food and Drug Administration for its
Covid-19 prophylaxis AZD7442.
If granted, AZD7442 would be the first long-acting antibody to
receive an EUA for Covid-19 prevention, AstraZeneca said.
Data from a Phase 3 trial showed a 77% reduction in the risk of
developing symptomatic Covid-19 with long-acting antibody
combination, the pharmaceutical company said.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com;
@JaimeLlinaresT
(END) Dow Jones Newswires
October 05, 2021 02:28 ET (06:28 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
